EUVIMEDEUVIMED entdecken
Open Access

Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression

Wenyi Jin, Yubiao Zhang, Zhijie Zhao, Mingyong Gao

Theranostics · 2024 · 14 (9) · 3439-3469

DOI: 10.7150/thno.93962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Wenyi Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai Unive…. Hauptthemen laut MEDLINE: Neuroblastoma, Tumor Microenvironment, Disease Progression, Etoposide. Die Arbeit wurde bisher 50-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Synergic reprogramming of metabolic dominates neuroblastoma (NB) progression. It is of great clinical implications to develop an individualized risk prognostication approach with stratification-guided therapeutic options for NB based on elucidating molecular mechanisms of metabolic reprogramming.

Methods

With a machine learning-based multi-step program, the synergic mechanisms of metabolic reprogramming-driven malignant progression of NB were elucidated at single-cell and metabolite flux dimensions. Subsequently, a promising metabolic reprogramming-associated prognostic signature (MPS) and individualized therapeutic approaches based on MPS-stratification were developed and further validated independently using pre-clinical models.

Results

MPS-identified MPS-I NB showed significantly higher activity of metabolic reprogramming than MPS-II counterparts. MPS demonstrated improved accuracy compared to current clinical characteristics [AUC: 0.915 vs. 0.657 (MYCN), 0.713 (INSS-stage), and 0.808 (INRG-stratification)] in predicting prognosis. AZD7762 and etoposide were identified as potent therapeutics against MPS-I and II NB, respectively. Subsequent biological tests revealed AZD7762 substantially inhibited growth, migration, and invasion of MPS-I NB cells, more effectively than that of MPS-II cells. Conversely, etoposide had better therapeutic effects on MPS-II NB cells. More encouragingly, AZD7762 and etoposide significantly inhibited in-vivo subcutaneous tumorigenesis, proliferation, and pulmonary metastasis in MPS-I and MPS-II samples, respectively; thereby prolonging survival of tumor-bearing mice. Mechanistically, AZD7762 and etoposide-induced apoptosis of the MPS-I and MPS-II cells, respectively, through mitochondria-dependent pathways; and MPS-I NB resisted etoposide-induced apoptosis by addiction of glutamate metabolism and acetyl coenzyme A. MPS-I NB progression was fueled by multiple metabolic reprogramming-driven factors including multidrug resistance, immunosuppressive and tumor-promoting inflammatory microenvironments. Immunologically, MPS-I NB suppressed immune cells via MIF and THBS signaling pathways. Metabolically, the malignant proliferation of MPS-I NB cells was remarkably supported by reprogrammed glutamate metabolism, tricarboxylic acid cycle, urea cycle, etc. Furthermore, MPS-I NB cells manifested a distinct tumor-promoting developmental lineage and self-communication patterns, as evidenced by enhanced oncogenic signaling pathways activated with development and self-communications.

Conclusions

This study provides deep insights into the molecular mechanisms underlying metabolic reprogramming-mediated malignant progression of NB. It also sheds light on developing targeted medications guided by the novel precise risk prognostication approaches, which could contribute to a significantly improved therapeutic strategy for NB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaTumor MicroenvironmentDisease ProgressionEtoposideHumansAnimalsMiceCell Line, TumorPrognosisCellular ReprogrammingCell ProliferationXenograft Model Antitumor AssaysMolecular Targeted TherapyMachine LearningApoptosisMetabolic Reprogramming

Stichwörter der Autor:innen

AZD7762etoposideimmune microenvironmentmetabolic reprogrammingneuroblastoma

Substanzen

Etoposide

Autor:innen und Institutionen

  • Department of Orthopedics, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, China, 325041.
  • Department of Orthopedics, Renmin Hospital of Wuhan University, No. 99 Zhangzhidong Road, Wuchang District, Wuhan, China, 430060.
  • Department of Biomedical Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong SAR, China, 999077.
  • Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, School of Medicine, Shanghai Jiao Tong University, 639 Zhi Zao Ju Road, Shanghai, China, 200011.

Zitieren

APA

Jin, W., Zhang, Y., Zhao, Z., & Gao, M. (2024). Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression. Theranostics, 14(9), 3439-3469. https://doi.org/10.7150/thno.93962

Vancouver

Jin W, Zhang Y, Zhao Z, Gao M. Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression. Theranostics. 2024;14(9):3439-3469. doi:10.7150/thno.93962

BibTeX
@article{Jin2024,
  author = {Jin, Wenyi and Zhang, Yubiao and Zhao, Zhijie and Gao, Mingyong},
  title = {Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression},
  journal = {Theranostics},
  year = {2024},
  volume = {14},
  number = {9},
  pages = {3439--3469},
  doi = {10.7150/thno.93962}
}
Kostenlos starten →